These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8620668)

  • 41. Preclinical and clinical activity of zileuton and A-78773.
    Bell RL; Lanni C; Malo PE; Brooks DW; Stewart AO; Hansen R; Rubin P; Carter GW
    Ann N Y Acad Sci; 1993 Nov; 696():205-15. PubMed ID: 8109828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics.
    Pauls JD; Simon RA; Daffern PJ; Stevenson DD
    Ann Allergy Asthma Immunol; 2000 Jul; 85(1):40-5. PubMed ID: 10923603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
    Machinist JM; Mayer MD; Shet MS; Ferrero JL; Rodrigues AD
    Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
    Zouboulis ChC; Saborowski A; Boschnakow A
    Dermatology; 2005; 210(1):36-8. PubMed ID: 15604543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome.
    Willemsen MA; Rotteveel JJ; Steijlen PM; Heerschap A; Mayatepek E
    Neuropediatrics; 2000 Feb; 31(1):1-3. PubMed ID: 10774987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
    Singh VP; Patil CS; Kulkarni SK
    Pharmacol Biochem Behav; 2005 Jul; 81(3):433-9. PubMed ID: 15935457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
    Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
    Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
    Fischer AR; McFadden CA; Frantz R; Awni WM; Cohn J; Drazen JM; Israel E
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1203-7. PubMed ID: 7551371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
    Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
    Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton.
    Gaber F; James A; Delin I; Wetterholm A; Sampson AP; Dahlén B; Dahlén SE; Kumlin M
    J Allergy Clin Immunol; 2007 May; 119(5):1267-8. PubMed ID: 17258303
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects.
    Larsson BM; Kumlin M; Sundblad BM; Larsson K; Dahlén SE; Palmberg L
    Respir Med; 2006 Feb; 100(2):226-37. PubMed ID: 15939582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
    Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW
    Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A-78773: a selective, potent 5-lipoxygenase inhibitor.
    Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
    J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
    Schwartz HJ; Petty T; Dubé LM; Swanson LJ; Lancaster JF
    Arch Intern Med; 1998 Jan; 158(2):141-8. PubMed ID: 9448552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats.
    Zarif A; Eiznhamer D; Callaghan C; Doria MI; Broutman L; Keshavarzian A
    Inflammation; 1996 Jun; 20(3):217-27. PubMed ID: 8796377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.
    Bertrán X; Mañé J; Fernández-Bañares F; Castellá E; Bartolí R; Ojanguren I; Esteve M; Gassull MA
    Gut; 1996 Jun; 38(6):899-904. PubMed ID: 8984030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
    Hui KP; Taylor IK; Taylor GW; Rubin P; Kesterson J; Barnes NC; Barnes PJ
    Thorax; 1991 Mar; 46(3):184-9. PubMed ID: 1851340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.